Page 994 - Read Online

Machado. Hepatoma Res 2020;6:84 I http://dx.doi.org/10.20517/2394-5079.2020.90 Page 15 of 18

52. Taylor R, Holman RR. Normal weight individuals who develop type 2 diabetes: the personal fat threshold. Clin Sci (Lond)
2015;128:405-10.
53. Du T, Yu X, Zhang J, Sun X. Lipid accumulation product and visceral adiposity index are effective markers for identifying the
metabolically obese normal-weight phenotype. Acta Diabetol 2015;52:855-63.
54. Neeland IJ, Ross R, Despres JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet
Diabetes Endocrinol 2019;7:715-25.
55. Zierath JR, Livingston JN, Thorne A, et al. Regional difference in insulin inhibition of non-esterified fatty acid release from human
adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway.
Diabetologia 1998;41:1343-54.
56. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic lipolysis in human obesity. J Clin Invest 2004;113:1582-8.
57. Feng R, Luo C, Li C, et al. Free fatty acids profile among lean, overweight and obese non-alcoholic fatty liver disease patients: a case -
control study. Lipids Health Dis 2017;16:165.
58. Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev 2013;93:359-404.
59. Wensveen FM, Valentic S, Sestan M, Turk Wensveen T, Polic B. The “Big Bang” in obese fat: events initiating obesity-induced adipose
tissue inflammation. Eur J Immunol 2015;45:2446-56.
60. Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic
syndrome and visceral fat accumulation. Am J Gastroenterol 2007;102:2708-15.
61. Park BJ, Kim YJ, Kim DH, et al. Visceral adipose tissue area is an independent risk factor for hepatic steatosis. J Gastroenterol Hepatol
2008;23:900-7.
62. Chung GE, Kim D, Kwark MS, et al. Visceral adipose tissue area as an independent risk factor for elevated liver enzyme in nonalcoholic
fatty liver disease. Medicine (Baltimore) 2015;94:e573.
63. Yu SJ, Kim W, Kim D, et al. Visceral obesity predicts significant fibrosis in patients with nonalcoholic fatty liver disease. Medicine
(Baltimore) 2015;94:e2159.
64. Choe EY, Lee YH, Choi YJ, et al. Waist-to-calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients
with type 2 diabetes. J Gastroenterol Hepatol 2018;33:1082-91.
65. Kure T, Mawatari S, Imamura Y, et al. Nonalcoholic fatty liver disease is associated with both subcutaneous and visceral adiposity: a
cross-sectional study. Medicine (Baltimore) 2019;98:e17879.
66. Kim D, Chung GE, Kwak MS, et al. Body fat distribution and risk of incident and regressed nonalcoholic fatty liver disease. Clin
Gastroenterol Hepatol 2016;14:132-8.e4.
67. Kim HJ, Kim HJ, Lee KE, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern
Med 2004;164:2169-75.
68. Yasutake K, Nakamuta M, Shima Y, et al. Nutritional investigation of non-obese patients with non-alcoholic fatty liver disease: the
significance of dietary cholesterol. Scand J Gastroenterol 2009;44:471-7.
69. Shida T, Oshida N, Suzuki H, et al. Clinical and anthropometric characteristics of non-obese non-alcoholic fatty liver disease subjects in
Japan. Hepatol Res 2020; doi: 10.1111/hepr.13543.
70. Nakamuta M, Kohjima M, Higuchi N, et al. The significance of differences in fatty acid metabolism between obese and non-obese
patients with non-alcoholic fatty liver disease. Int J Mol Med 2008;22:663-7.
71. Karpe F, Pinnick KE. Biology of upper-body and lower-body adipose tissue--link to whole-body phenotypes. Nat Rev Endocrinol
2015;11:90-100.
72. Sahakyan KR, Somers VK, Rodriguez-Escudero JP, et al. Normal-weight central obesity: implications for total and cardiovascular
mortality. Ann Intern Med 2015;163:827-35.
73. Snijder MB, Zimmet PZ, Visser M, Dekker JM, Seidell JC, Shaw JE. Independent and opposite associations of waist and hip
circumferences with diabetes, hypertension and dyslipidemia: the AusDiab Study. Int J Obes Relat Metab Disord 2004;28:402-9.
74. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-
control study. Lancet 2005;366:1640-9.
75. Tchoukalova YD, Votruba SB, Tchkonia T, Giorgadze N, Kirkland JL, Jensen MD. Regional differences in cellular mechanisms of
adipose tissue gain with overfeeding. Proc Natl Acad Sci U S A 2010;107:18226-31.
76. Pinnick KE, Nicholson G, Manolopoulos KN, et al. Distinct developmental profile of lower-body adipose tissue defines resistance against
obesity-associated metabolic complications. Diabetes 2014;63:3785-97.
77. Lotta LA, Gulati P, Day FR, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis
of human insulin resistance. Nat Genet 2017;49:17-26.
78. Zheng RD, Chen ZR, Chen JN, Lu YH, Chen J. Role of body mass index, waist-to-height and waist-to-hip ratio in prediction of
nonalcoholic fatty liver disease. Gastroenterol Res Pract 2012;2012:362147.
79. Lee YH, Kim SU, Song K, et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in
nonalcoholic fatty liver disease: nationwide surveys (KNHANES 2008-2011). Hepatology 2016;63:776-86.
80. Hong HC, Hwang SY, Choi HY, et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean sarcopenic
obesity study. Hepatology 2014;59:1772-8.
81. Issa D, Alkhouri N, Tsien C, et al. Presence of sarcopenia (muscle wasting) in patients with nonalcoholic steatohepatitis. Hepatology
2014;60:428-9.
82. Koo BK, Kim D, Joo SK, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J